RT Journal Article
SR Electronic
T1 Antibody binding and ACE2 binding inhibition is significantly reduced for the Omicron variant compared to all other variants of concern
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.30.21267519
DO 10.1101/2021.12.30.21267519
A1 Daniel Junker
A1 Matthias Becker
A1 Teresa R. Wagner
A1 Philipp D. Kaiser
A1 Sandra Maier
A1 Tanja M. Grimm
A1 Johanna Griesbaum
A1 Patrick Marsall
A1 Jens Gruber
A1 Bjoern Traenkle
A1 Constanze Heinzel
A1 Yudi T. Pinilla
A1 Jana Held
A1 Rolf Fendel
A1 Andrea Kreidenweiss
A1 Annika Nelde
A1 Yacine Maringer
A1 Sarah Schroeder
A1 Juliane S. Walz
A1 Karina Althaus
A1 Gunalp Uzun
A1 Marco Mikus
A1 Tamam Bakchoul
A1 Katja Schenke-Layland
A1 Stefanie Bunk
A1 Helene Haeberle
A1 Siri Göpel
A1 Michael Bitzer
A1 Hanna Renk
A1 Jonathan Remppis
A1 Corinna Engel
A1 Axel R. Franz
A1 Manuela Harries
A1 Barbora Kessel
A1 Monika Strengert
A1 Gerard Krause
A1 Anne Zeck
A1 Ulrich Rothbauer
A1 Alex Dulovic
A1 Nicole Schneiderhan-Marra
YR 2022
UL http://medrxiv.org/content/early/2022/01/01/2021.12.30.21267519.abstract
AB The rapid emergence of the Omicron variant and its large number of mutations has led to its classification as a variant of concern (VOC) by the WHO(1). Initial studies on the neutralizing response towards this variant within convalescent and vaccinated individuals have identified substantial reductions(2-8). However many of these sample sets used in these studies were either small, uniform in nature, or were compared only to wild-type (WT) or, at most, a few other VOC. Here, we assessed IgG binding, (Angiotensin-Converting Enzyme 2) ACE2 binding inhibition, and antibody binding dynamics for the omicron variant compared to all other VOC and variants of interest (VOI)(9), in a large cohort of infected, vaccinated, and infected and then vaccinated individuals. While omicron was capable of binding to ACE2 efficiently, antibodies elicited by infection or immunization showed reduced IgG binding and ACE2 binding inhibition compared to WT and all VOC. Among vaccinated samples, antibody binding responses towards omicron were only improved following administration of a third dose. Overall, our results identify that omicron can still bind ACE2 while pre-existing antibodies can bind omicron. The extent of the mutations appear to inhibit the development of a neutralizing response, and as a result, omicron remains capable of evading immune control.Competing Interest StatementNSM was a speaker at previous Luminex user meetings. The NMI is involved in applied research projects as a fee for services with the Luminex Corporation. All other authors declare no competing interests.Funding StatementThis work was financially supported by the State Ministry of Baden-Wuerttemberg for Economic Affairs, Labour and Housing Construction (grant numbers FKZ 3-4332.62-NMI-67 and FKZ 3-4332.62-NMI-68), the Initiative and Networking Fund of the Helmholtz Association of German Research Centres (grant number SO-96), the EU Horizon 2020 research and innovation program (grant agreement number 101003480 - CORESMA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed written consent was obtained from all study participants. Ethical approval and oversight for the samples used in this study was provided by the following ethics committees: the Ethics Committee of the University Hospital Tuebingen (293/2020BO2, 764/2020/BO2 (amended 6.12.21), B312/2020BO1 (amended 02.06.21), 556/2021BO1), the Ethics Committee of the University of Tuebingen (179/2020/BO2, 188/2020A) and the Ethics Committee of Hannover Medical School (9086_BO_S_2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.